TY - JOUR
T1 - Interobserver agreement of interim and end-of-treatment18F-FDG PET/CT in diffuse large B-cell lymphoma
T2 - Impact on clinical practice and trials
AU - Burggraaff, Coreline N.
AU - Cornelisse, Alexander C.
AU - Hoekstra, Otto S.
AU - Lugtenburg, Pieternella J.
AU - De Keizer, Bart
AU - Arens, Anne I.J.
AU - Celik, Filiz
AU - Huijbregts, Julia E.
AU - De Vet, Henrica C.W.
AU - Zijlstra, Josée M.
N1 - Funding Information:
This work was financially supported by an Alpe d’HuZes/KWF fund, provided by the Dutch Cancer Society (VU 2012-5848). Pie-ternella Lugtenburg has received research funding from Roche, Servier, and Takeda and honoraria for advisory boards from Roche, Servier, Sandoz, BMS, Genmab, Takeda, and Celgene. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
COPYRIGHT © 2018 by the Society of Nuclear Medicine and Molecular Imaging.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - We aimed to assess the interobserver agreement of interim PET (I-PET) and end-of-treatment PET (EoT-PET) using the Deauville score (DS) in first-line diffuse large B-cell lymphoma (DLBCL) patients. Methods: I-PET and EoT-PET scans of DLBCL patients were performed in the HOVON84 study (2007–2012), an international multicenter randomized controlled trial. Patients received R-CHOP14 and were randomized to receive rituximab intensification in the first 4 cycles or not. I-PET was performed after 4 cycles (for observational purposes), and EoT-PET after 6 or 8 cycles. Two independent central reviewers retrospectively scored all scans according to the DS system, masked to clinical outcomes. Results were dichotomized as negative (DS of 1–3) or positive (DS of 4–5). Besides percentage overall agreement (OA), we calculated agreement for positive and negative scores, expressed as positive agreement (PA) and negative agreement (NA), respectively. Results: 465 I-PET and 457 EoT-PET scans were centrally reviewed; baseline18F-FDG PET or PET/CT was available in 75%–77%, and CT in the remaining cases. Percentage OA for I-PET and EoT-PET were 87.7% and 91.7% (P 5 0.049), with NA of 92.0% and 95.0% (P 5 0.091), and PA of 73.7% and 76.3% (P 5 0.656), respectively. Conclusion: Interobserver agreement using DS in DLBCL patients in I-PET and EoT-PET yields high OA and NA. The lower PA suggests that EoT-PET/CT treatment evaluation in daily practice and I-PET–adapted trials may benefit from dual reads and central review, respectively.
AB - We aimed to assess the interobserver agreement of interim PET (I-PET) and end-of-treatment PET (EoT-PET) using the Deauville score (DS) in first-line diffuse large B-cell lymphoma (DLBCL) patients. Methods: I-PET and EoT-PET scans of DLBCL patients were performed in the HOVON84 study (2007–2012), an international multicenter randomized controlled trial. Patients received R-CHOP14 and were randomized to receive rituximab intensification in the first 4 cycles or not. I-PET was performed after 4 cycles (for observational purposes), and EoT-PET after 6 or 8 cycles. Two independent central reviewers retrospectively scored all scans according to the DS system, masked to clinical outcomes. Results were dichotomized as negative (DS of 1–3) or positive (DS of 4–5). Besides percentage overall agreement (OA), we calculated agreement for positive and negative scores, expressed as positive agreement (PA) and negative agreement (NA), respectively. Results: 465 I-PET and 457 EoT-PET scans were centrally reviewed; baseline18F-FDG PET or PET/CT was available in 75%–77%, and CT in the remaining cases. Percentage OA for I-PET and EoT-PET were 87.7% and 91.7% (P 5 0.049), with NA of 92.0% and 95.0% (P 5 0.091), and PA of 73.7% and 76.3% (P 5 0.656), respectively. Conclusion: Interobserver agreement using DS in DLBCL patients in I-PET and EoT-PET yields high OA and NA. The lower PA suggests that EoT-PET/CT treatment evaluation in daily practice and I-PET–adapted trials may benefit from dual reads and central review, respectively.
KW - Deauville score
KW - DLBCL
KW - Lugano criteria
KW - Observer variation
KW - Positron emission tomography
KW - observer variation
KW - positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=85057602332&partnerID=8YFLogxK
U2 - 10.2967/jnumed.118.210807
DO - 10.2967/jnumed.118.210807
M3 - Article
AN - SCOPUS:85057602332
SN - 0161-5505
VL - 59
SP - 1831
EP - 1836
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 12
ER -